Clinical and Basic Research
The fellow may participate in any of the ongoing research projects but will be encouraged to design and implement a project that could be conducted over the course of his/her fellowship. This should be of the nature to yield at least two publications in peer reviewed journals.
The current ongoing projects fall under one of the following areas:
- Heart Failure
- Post-transplant: Cardiac Allograft Vasculopathy
- Multi-Center Research Trials
1) Heart failure drug trials
2) CHF and arrhythmia - ICD versus drug therapy.
A strong commitment to basic research needs to be present since these projects take a long time just to learn the investigational techniques.
- Endothelial function using Flusol
- NC020 in the diet may improve endothelial function in a transplant model
- Endothelial cell/smooth muscle cell proliferation in response to lymphocyte stimulated cytokine production
- Changes in oxidative metabolism in rejection and CAD
- In-vivo gene transfer in a transplanted heart
- Myoblast transplantation in a porcine model
The following is a list of the current ongoing trials in which the fellow may participate.
- Amlodipline versus placebo effect on survival of patients with CHF
- IV administration of TRK-820 to patients with hyponatremia coincident with CHF
- Prevention of sudden cardiac death in heart failure
- Acute hemodynamic effects of IV L-753,037 in patients with symptomatic heart failure
- Mycophenolate mofetil or azathioprine in combination with cyclosporin and corticosteroids for rejections, grafts and patient survival in cardiac allograft recipients
- Neoral versus Sandimmune for safety, tolerability and vascular effects in cardiac transplant patients
- Tacrolimus and cyclosporin regimens in cardiac transplant patients
- Chronic use vesnarinone in heart failure
- Effects of Bosentan on morbidity of patients with moderate to severe CHF
- Effect of oral Azimilide Dihydrochloride versus placebo on survival in recent post MI patients at risk of sudden cardiac death
- WCD pre market approval investigational plan
- IV milrinone versus placebo in reduction of hospital days in the 60 days following entry into study for treatment of left-sided heart failure (milrinone exacerbations of CHF)
- Oral levosimendan as substitute for IV inotropic support on end-stage heart failure